Fulcrum Therapeutics financials
$3.70−0.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $80.0M | $2.8M | $6.3M | — |
| Gross profit | $0.00 | $80.0M | $2.8M | $6.3M | — |
| Gross margin | — | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$84.8M | -$21.9M | -$110.7M | -$112.1M | -$84.2M |
| Net income | -$74.9M | -$9.7M | -$97.3M | -$109.9M | -$89.8M |
| Net margin | — | −12.2% | −3470.1% | −1732.4% | — |
| Diluted EPS | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-8.13 |
| EBITDA | -$83.4M | -$18.2M | -$108.5M | -$109.7M | -$82.2M |
| Operating cash flow | -$60.1M | -$2.2M | -$91.0M | -$97.0M | -$39.5M |
| Free cash flow | -$60.4M | -$2.5M | -$91.5M | -$99.0M | -$40.3M |
| Diluted shares | 63.4M | 62.0M | 61.3M | 45.0M | 11.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $197.5M | $58.2M | $25.6M | $35.1M | $35.4M | $57.1M |
| Short-term investments | $154.8M | $182.8M | $210.7M | $167.8M | $182.8M | $55.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $469.0K | $469.0K |
| Total assets | $366.3M | $260.7M | $257.7M | $226.7M | $235.0M | $129.6M |
| Total liabilities | $17.3M | $17.7M | $22.5M | $27.7M | $23.5M | $34.4M |
| Shareholders' equity | $349.0M | $243.0M | $235.2M | $198.9M | $211.5M | $95.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology